1.0 Policy statement

Patients admitted on hydroxyurea shall not be given hydroxyurea prescription on discharge. **Haematology is to prescribe in order to monitor blood work.**

2.0 Definitions

- **Hydroxyurea (HU)** is a chemotherapy medicine that has been used to treat many disorders, including sickle cell disease (SCD). Research has shown that patients with sickle cell disease who take hydroxyurea are admitted to hospital because of painful events only half as often as patients who do not take hydroxyurea, have fewer acute chest crises and have less need for blood transfusions if they are admitted to hospital. Please see [www.aboutkidshealth.ca](http://www.aboutkidshealth.ca).

- **Maximum Therapeutic Dose (MTD)** is maximum dose or clinical efficacy achieved.

- **Transcranial Doppler (TCD)** is a non-invasive ultrasound used to screen for strokes measuring the rate of blood flow through the large vessels on both sides of the brain.

- **Vaso-Occlusive Crises (VOC)** are blockages of the blood vessels anywhere in the body by deformed red blood cells. This causes a lack of oxygen in the affected area of the body. Symptoms depend on where the blood vessels are blocked.
### 3.0 Guideline

**Sickle Cell Disease: Guidelines to Hydroxyurea**

- **Indications for hydroxyurea**
  - In infants 6 months of age, children, and adolescents with SCA, offer treatment with hydroxyurea regardless of clinical severity to reduce SCD-related complications. Refer to NIH guidelines.
  - At least 2 hospitalizations for Vaso-Occlusive Crises (VOC) episodes in a 12-month calendar period.
  - 5 or 3 acute chest crises requiring transfusions.
  - Echographic or radiographic evidence of organ damage due to VOC pain managed at home.
  - Sickle Cell Trait.
  - Abnormal Transcranial Doppler (TCD) in patient failing translation therapy.
  - Chronic hypoxemia.
  - Low hemoglobin < 70 g/L.
  - High conditional TCD velocities.
  - Presence of silent infarcts on screening.
  - Poor growth and development.

- **Prior to starting hydroxyurea ensure that the following is reviewed:**
  - Evidence of organ damage – TCD velocities, proteinuria, hypoxemia, academic performance.
  - Does the patient have sleep apnea?
  - Psychological issues which might impact compliance with treatment regimen such as transportation, and finances for drug or range.
  - Document growth and development.
  - Thorough physical examination.
  - Document discussion, history and physical including height and weight, oxygen saturations, and laboratory reports.

- **Evidence of organ damage**
  - **Low hemoglobin** ≤ 70 g/L.
  - **High conditional TCD velocities**.
  - **Presence of silent infarcts on screening**.
  - **Poor growth and development**.

- **Ongoing monitoring of bloodwork**
  - **Monitoring**
    - CBC x 1.
    - Q 6 months.
    - HB analysis, LDH, AST, ALT, BUN.
  - **Threshold for Dose Reductions**
    - Neutrophil ANC < 2 x 10^9/L.
    - Retic count < 1 x 10^6/L.
    - Hemoglobin ≤ 70 g/L.
  - If Hematologic Toxicity Occurs
    - Discontinue hydroxyurea until counts recover (usually 5-7 days).
    - Restart at same dose. If threshold is again reached, reduce to previous dose and then to maximum therapeutic dose.

- **Patient and Family Involvement**
  - **Clinical effect**
    - Review of VOC episodes with family.
    - Side effects.
    - Hematologic toxicity and beneficial effects.
    - Keep patient involved in management. This improves compliance and instills confidence in taking the drug.
    - Celebrate beneficial effects, and be open when toxicities occur. Show graphs of response e.g. MCV > 106.

### 4.0 Related Documents

- **Dissolve and Dose Drug Administration**
- **Chemotherapy At Home: Safely Handling and Giving Medicines**
- **Chemotherapy At Home: Safely Giving Your Child Capsules**
- **Hydroxyurea Education and Discussions Tip Sheet**

© The Hospital for Sick Children (“SickKids”). All Rights Reserved. This document was developed solely for use at SickKids. SickKids accepts no responsibility for use of this material by any person or organization not associated with SickKids. A printed copy of this document may not reflect the current, electronic version on the SickKids Intranet. Use of this document in any setting must be subject to the professional judgment of the user. No part of the document should be used for publication without prior written consent of SickKids.
5.0 References


7. The effect of prolonged administration of Hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes;results of a 17-year, single center trial (LaSHS). Blood 2010;115(12):2354-2363


9. Ware, RE. How I use hydroxyurea to treat sickle cell disease. Blood 1 July 2010.Vol 115, Number 26

Revised by:

- Melina Cheong, RN, Nurse Practitioner, Division of Haematology/Oncology
- Melanie Kirby, MD, Staff Physician, Division of Haematology/Oncology
- Marina Strzelecki, Clinical Pharmacist, Pharmacy

Attachments:

- Hydroxyurea Education and Discussions Tip Sheet.pdf
- Revision History.docx
- scd_hydroxyurea_v4_2021.pdf